Abstract: The present invention provides processes for preparing calcium salts of statin, particularly rosuvastatin calcium salt substantially free of impurities on an industrial scale.

Abstract: The present invention relates to a new process for the synthesis of high purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine of formula (I) using 2,3-dichlorobenzoyl cyanide and an aminoguanidine salt as starting materials. 2,3-dichlorobenzoyl cyanide is reacted with 1-2 mol equivalent of aminoguanidine salt in 3-6 mol equivalent of methanesulfonic acid, then the obtained adduct of formula (IV) is transformed without isolation into the product with magnesium oxide.

Abstract: The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Abstract: The invention relates to a method and a device for producing melamine by means of the thermal conversion of urea. The invention is characterized in that: a) urea is reacted to form melamine at least partially under reaction conditions wherein an educt, an intermediate and/or an end product are present in a supercritical state; and b) the mixture consisting of at least one educt, an intermediate and/or an end product essentially forms a homogeneous phase and all educts, intermediates, and/or end products are in a complete solution. The single-phase reaction results in an especially efficient reaction.

Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.

Abstract: The invention relates to a high pressure method for producing pure melamine by pyrolyzing urea in a vertical synthesis reactor. The synthesis reactor has three stages above one another: a) in the first stage, the smaller portion of the total amount of urea is introduced into the central tube of a first tank reactor forming a first melamine-containing reaction medium; b) in the second stage, the first melamine-containing reaction medium and the larger portion of the total amount of urea is introduced into the central tube of a second tank reactor forming a second melamine-containing reaction medium; c) in the third stage, the second melamine-containing reaction medium is introduced into a vertical tubular flow reactor forming a raw melamine melt that is processed to obtain pure melamine.

Abstract: Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholsterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis wherein X is N or CR5; and pharmaceutically acceptable salts thereof, wherein R1 to R7 are as defined herein. A method for treating the above diseases employing the above compounds is also provided.

Abstract: A process is described for preparing alkoxycarbonylaminotriazines by reacting di- or triaminotriazines with dimethyl carbonate in the presence of an alcohol and of an alkali metal or alkaline earth metal methoxide base.

Abstract: Compounds of the formulae wherein, provided that at least one of R1, R2, and R3 is not a hydrogen atom, R1, R2, and R3 each, independently of the other, is hydrogen, alkyl, aryl, arylalkyl, or alkylaryl, and wherein R1 and R2 can also be alkoxy aryloxy, arylalkyloxy, alkylaryloxy, polyalkyleneoxy, polyaryleneoxy, polyarylalkyleneoxy, polyalkylaryleneoxy, silyl, siloxane, polysilylene, polysiloxane, or a group of the formula wherein r and s are integers representing a number of repeat —CH2— groups, and wherein X is a direct bond, oxygen, sulfur, —NR40— wherein R40 is hydrogen, alkyl, aryl, arylalkyl, or alkylaryl, or —CR50R60— wherein R50 and R60 each, independently of the other, is hydrogen, alkyl, aryl, arylalkyl, or alkylaryl, and R10 and R11 each, independently of the other, is alkylene, arylene, arylalkylene, or alkylarylene, and wherein R10 can also be polyalkyleneoxy, polyaryleneoxy, polyarylalkyleneoxy, polyalkylaryleneoxy, silylene, siloxane, polysilylene, or polysiloxane.

Abstract: This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: wherein E is nitrogen or C—R?; J is sulfur or oxygen; R?, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrite, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural ?-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases in the presence of thiol.

Abstract: The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.

Abstract: This invention relates to a compound capable of binding to a picornavirus capsid comprising two or more capsid binding moieties.

Abstract: This invention relates to a process for making spirolactone compounds analogous to formula I

Abstract: The present invention relates to 2-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, having the formula: and pharmaceutical compositions thereof, and methods for controlling the level of one or more inflammation inducing cytokines selected from the group consisting of, interleukin-1 (IL-1), Tumor Necrosis Factor-? (TNF-?), interleukin-6 (IL-6), and interleukin-8 (IL-8), thereby controlling, mediating, or abating disease states affected by the level of extracellular inflammatory cytokines in humans.

Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I): and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]triazine compounds as inhibitors of kinases such as, for example, cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the kinases using such compounds or pharmaceutical compositions.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, SAPK2? and SAPK2? kinases.

Abstract: A stabilizer composition comprising (A) a compound of the formula (I) wherein R is (CH2—CH2—O—)n, —R2; —CH2—CH(OH)—CH2—O—R2; or —CH(R3)—CO—O—R4; n is 0 or 1; R2 is C1-C13alkyl or C2C20alkenyl or C6-C12aryl or CO—C1-C18alkyl; R3 is H or C1-C8 alkyl; R4 is C1-C12alkyl or C2-C12alkenyl or C5C6cycloalkyl; and (B) one or more compounds selected from benzotriazoles of the formula (IIa), 2-hydroxybenzophenones of the formula (IIb), oxalanilides of the formula (IIc), 2-hydroxyphenyltriazines of formula (IId), cinnamates of formula (IIe), and benzoates of formula (IIf) as defined in claim 1, is especially effective towards stabilizing organic materials against degradation induced by light, heat or oxidation.

Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.